Lead Optimization

We optimize your lead compounds using expertise and data-driven decisions

The lead optimization stage marks the end of the drug discovery phase and the start of pharmaceutical or biological development. Insight into the absorption, distribution, metabolism, and excretion (ADME) is key to progressing your identified lead compounds after the hit to lead phase.

We support you in the further investigation of their target specificity, pharmacokinetic properties, bioavailability, and safety profiles by offering relevant in vitro and in vivo models, cost-efficient methods, and a key selection of assays using data-driven decision making.

Our Approach

We operate as a unified, committed, accessible team in solving your challenges quickly

Our study directors and technical specialists support you in the selection of your lead compounds with proof of effectiveness, decreased toxicity and absorption properties.

Making use of our portfolio of in vitro and in vivo models combined with in-depth and robust readouts from our state-of-the-art biomarker and imaging equipment, we can apply a data-driven and risk-based approach to this stage of your compound development.

Our team of experts consider your entire development journey when recommending cost-efficient solutions to reach your research milestones. We leverage our network of specialists to reduce your timeline and progress your compound more effectively to the patients that need it most.

Contact an expert and let’s advance your lead compounds

Lead Optimization Techniques

InnoSer has experienced and dedicated study directors that manage and guide a proactive and effective study design along with a team of associates and bio technicians to help achieve high-quality service and results. With in-depth knowledge of our models and areas of therapeutic expertise we streamline the selection process to ensure robust results and fast progression. With our in vitro and in vivo facilities, we can support ADME and custom studies with the assessment of lead drug metabolites and relevant biomarkers. Through qualified partners we also offer pharmacometric assessment of lead-compounds. By estimating clinical pharmacokinetics, in-silico, early on in drug development this helps to assess clinical feasibility and reduce risk in your pipeline

We provide the following crucial services that are specific to the progression of your compound into the preclinical phase.

In Vivo Pharmacology

Early assessment of DMPK properties
Efficacy
PK feasibility
Metabolic stability
Proof-of-Concept Studies
MTD (Maximum Tolerated Dose) determination
Dose frequency
Dose response relations
Therapeutic efficacy in in vivo disease model

In Vivo DMPK

Assess route of administration
Bioavailability
Drug distribution
DRF (Dose Range Finding)
Preclinical efficacy

Toxicology

Single Dose Toxicity
Repeated Dose Toxicity
Toxicokinetics

Biomarker Assessment

Custom assay development and validation
Meso Scale Discovery
ELISA
IHC
Flow Cytometry
High Content Imaging

Imaging capabilities:

With our state-of-the-art equipment we can perform high content cellular imaging which supports compound prioritization and timely decision-making during the hit to lead and lead optimization phases of the drug development project.

Flow cytometry gives us the ability to analyze heterogeneous cell populations at specific time points making it a useful tool for testing drug-cell interactions.

Partnering with us will give you access to Meso Scale Discovery (MSD) testing services ideal for immunogenicity testing and multiplex biomarker assays

Navigate The Drug Development Pipeline

Do you want to streamline your preclinical research?

Questions about how our services can answer your research questions? Reach out to one of our experts today and we can provide you with tailored advice on getting started.

Contact an Expert